Respironics Acquires PAM-RL Objective Limb Activity Monitor

Murrysville, PA - February 28, 2007

PAM Respironics, Inc . (NASDAQ/NMS Symbol: RESP) announces the acquisition from IM Systems of the PAM-RL , an objective activity monitoring device used to record and analyze Periodic Limb Movements (PLMs). PLMs can disrupt sleep, or delay sleep onset, and are often associated with Restless Legs Syndrome (RLS) and other neurological disorders.

The PAM-RL device provides researchers and clinicians with a quantifiable method for assessing limb movements. This assessment can be applied in the research environment to studying the efficacy of drug formulations and/or medical devices designed to treat RLS.

Easily worn around the ankle, the noninvasive device enables freedom of movement by the user as there are no leads or tethers. While typically worn at night during sleep, the PAM-RL can record leg movements for more than five consecutive days. After the data are recovered from the device, they are analyzed to determine the frequency of PLM events.

Special features of the device include nonvolatile memory, 5.2 days of continuous recording, a body position switch which automatically detects if the wearer is in an upright or down position, and a software application that automatically analyzes the recorded data to provide PLMs per hour.

According to Dennis Dalangin, marketing manager, "The PAM-RL is the first tool to record PLMs outside of a sleep lab or clinical trial environment. Instead of subjects spending time in a lab, they are able to remain in the comfort of their own homes and go about their normal daily activities. This patient benefit, along with ease of use, low-cost and physician-friendly features - such as high resolution data and an up/down sensor - make the PAM-RL an effective alternative to expensive and cumbersome methods required by sleep labs."

RLS affects up to 10 percent of the US adult population. Symptoms include:

Involuntary twitching or overwhelming need to move the limbs
Sensations described as crawling, creeping, tingling, or pulling, especially at night
Inability to sit or lie still for extended periods of time
Severe sleep deprivation
Relief associated with walking

The PAM-RL actigraphy device will be distributed from the Respironics' Bend, Oregon facility. Additional product offerings include actigraphy devices such as the Actiwatch ® sleep/wake activity monitors and the Actical ® and Actiheart ® energy expenditure monitors.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,900 associates worldwide. Further information can be found on the Company's Web site: www.respironics.com.

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales, acceptance, and quality of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements, enforcement actions, product recalls or related field actions; future results from acquisitions and strategic investments; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States; foreign currency fluctuations; the effects of a major earthquake, cyber-attack or other catastrophic event that results in the destruction or disruption of any critical business or information technology systems; customer consolidation and concentration; increasing price competition and other competitive factors in the manufacture, distribution, and sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Company's stock price; and third party reimbursement; all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.